IPVS statement moving towards elimination of cervical cancer as a public health problem

Grants

Funding Acknowledgements

[ "Professor Suzanne Garland, has received Grants to her institution from Commonwealth Department of Health for HPV genoprevalance surveillance post vaccination, Merck and GSK (GlaxoSmithKline) to perform phase 3 clinical vaccine trials: Merck for an investigator initiated grant to evaluate HPV in RRP post vaccination programme, Seqirus for HPV in Australian cervical cancer HPV genotyping study, & VCA (Victoria Cancer Agency) for a study on effectiveness of public health HPV vaccine on HPV genoprevalence and CIN3 in vaccine-eligible age women. She has received speaking fees from MSD for work performed in her personal time and Merck paid for travel & accommodation to present at HPV Advisory board meetings.", "Dr. Giuliano's institution has received investigator initiated research grants from Merck & Co, Inc. on her behalf. She is also a member of the Scientific Advisory Board and Global Advisory Board of Merck & Co, Inc.", "Joel Palefsky: Merck and Co: scientific advisory board, grant support, travel support. No funds to me or my institution.", "Antiva Biosciences: Grant support, advisory board", "Agenovir: Grant support" ]